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Abstract: Incremental advances over the last two decades in the treatment of stage IV metastatic 
breast cancer (MBC) have resulted in signiﬁ  cantly prolonging the average life expectancy. In 
2008, the estimated 5-year relative survival rate for MBC is 27% which compares favorably to 
rates in stage IV lung (3%) and pancreatic cancers (1%). Despite these advances, MBC remains 
an incurable disease, often associated with many symptoms and a decreased quality of life 
(QoL). Therefore, therapy goals in the treatment of MBC include prolonging both progression-
free survival and overall survival rates, while at the same time improving QoL by palliation of 
symptoms. Therefore, systemic chemotherapy ideally should not induce unnecessary toxicities. 
Once chemotherapy is indicated, a number of drugs and regimens are available but only a few 
offer both palliation of symptoms (responses to therapy) and overall survival beneﬁ  t. The addition 
of novel biologic compounds to chemotherapy has been shown in phase III trials to improve 
all the above mentioned clinical outcomes in MBC. This review will discuss data supporting 
the use of gemcitabine/taxane combinations in the treatment of MBC.
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Introduction
Breast cancer remains a major public health problem for women. For 2008, in the 
US alone, there are estimated to be 180,460 new cases of breast cancer (Jemal et al 
2008). Despite many advances in the treatment of breast cancer, it remains the second 
most common cause of cancer related mortality with 40,480 estimated deaths to occur 
this year alone (Jemal et al 2008). Although metastatic breast cancer (MBC) remains 
largely incurable, as is the case in most other advanced solid tumors, improvements 
in systemic chemotherapy and endocrine therapy have prolonged the average life 
expectancy of patients with MBC. Estimated 5-year relative survival rate for MBC is 
27% (Jemal et al 2008). While not as good as the 5-year rates for stage IV testicular 
cancer (70%), which in many cases is curable with systemic chemotherapy, in 
comparison with survival rates for lung (3%) and pancreatic cancers (1.7%), MBC is 
a very treatable disease. In all patients regardless of HER-2/neu or hormone receptor 
status, chemotherapy remains an important component of the treatment of MBC. 
Taxane-nucleoside analog combinations remain among the most active drugs for the 
treatment of MBC and have been shown in randomized phase III trials to be superior 
to single agent therapy in anthracycline-pretreated patients (O’Shaughnessy et al 
2002; Albain et al 2008).
Gemcitabine and rationale for combination 
over single-agent therapy in MBC
The nucleoside analog gemcitabine (2’, 2’-diﬂ  uoro-deoxycytidine) is activated intra-
cellularly by phosphorylation into di- and tri-phosphates by the enzyme deoxycytidine 
kinase. The tri phosphate form of gemcitabine competes with deoxycytidine Therapeutics and Clinical Risk Management 2008:4(6) 1158
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triphosphate for incorporation into DNA and the di-phosphate 
form inhibits ribonucleotide reductase inhibiting DNA syn-
thesis (Huang et al 1991). Once incorporated, it determines 
fragmentation with consequent cell death (Plunkett et al 
1995). Gemcitabine has signiﬁ  cant clinical activity in MBC 
and other solid tumors. Results from a recent phase III ran-
domized trial demonstrated that gemcitabine in combination 
with paclitaxel as ﬁ  rst-line therapy in MBC resulted in sig-
niﬁ  cant improvements in both median overall survival (OS) 
and time to progression (TTP) over that of paclitaxel alone 
(Albain et al 2008). Emerging data from other phase III trials 
have reported combination chemotherapy to be superior to 
single-agent as ﬁ  rst- (O’Shaughnessy et al 2002; Beslija et al 
2006; Melemed et al 2007) or second- or third-line therapy 
(Martin et al 2007).
This growing body of data with taxane and nucleoside 
analog combinations provides evidence refuting the notion 
that in MBC combination chemotherapeutic agents are not 
superior to sequential single agents. By contrast, the E1193 
study (Sledge et al 2003), while showing signiﬁ  cant improve-
ments in overall response rates (ORR) and time to treatment 
failure with combining doxorubicin and paclitaxel, this did 
not translate into a signiﬁ  cant difference in TTP and OS 
compared to either drug alone in a sequential fashion. This 
study was instrumental in changed practice early 2000s: the 
preferential treatment of MBC was single sequential use of 
drugs. This changed substantially when the combination of 
capecitabine and docetaxel (O’Shaughnessy et al 2002) and 
gemcitabine and paclitaxel (Albain et al 2008) were pre-
sented and published both demonstrating the advantage in 
response rate, progression-free survival (PFS) and OS. The 
latter study demonstrated considerably less adverse toxici-
ties thus making it the preferred chemotherapy combination 
regimen for ﬁ  rst-line MBC (Moinpour et al 2004).
However, despite the superiority of taxane-nucleoside 
analog combinations, there are several clinical situations 
where single agent therapy would be preferable to combi-
nation therapy in MBC which we will also discuss in this 
review.
Rationale for non-anthracycline-
containing regimens in MBC
The widespread use of anthracyclines in the adjuvant setting, 
coupled with their cardiac and leukemogenic toxicities, has 
warranted the investigation of non-anthracycline alternatives. 
Non-anthracycline regimens are being studied in comparison 
with anthracycline-containing regimens in MBC and have 
been shown to be equal in efﬁ  cacy. An example of one 
such study is the combination of capecitabine/paclitaxel 
(XP), which was compared with epirubicin/paclitaxel 
(EP). The results showed that the median PFS for EP was 
11.8 months vs 12.3 months for XP (p = ns). There was no 
difference in OS. Response rates were 41% for EP and 41.5% 
for XP, supporting the argument that non-anthracycline-
containing regimens are at least as effective as anthracycline-
containing regimens (Lück et al 2007). In this article we will 
review currently available data in the treatment of MBC with 
gemcitabine in combination with docetaxel, paclitaxel, or 
nab-paclitaxel. We will also review the preclinical evidence 
supporting the use of gemcitabine/taxane combinations in 
the clinical setting of MBC.
Single-agent gemcitabine in MBC
Phase II data
Monotherapy with gemcitabine has been studied in many 
phase II studies with reported ORR between 14% and 37% 
as ﬁ  rst-line therapy, and approximately 12% and 30% as 
second-line therapy after prior taxanes or anthracyclines 
(Silvestris et al 2008).
Gemcitabine and taxanes
Taxanes are a class of drugs that do not have overlapping side 
effects with gemcitabine and hence combinations of these 
agents with gemcitabine are feasible. Moreover, the addition 
of gemcitabine to taxanes in MBC patients, have led to 
improved ORR, and with paclitaxel demonstrated signiﬁ  cant 
improvements in OS and TTP over paclitaxel alone.
Gemcitabine and paclitaxel
There are abundant pre-clinical data suggesting that the 
addition of paclitaxel to gemcitabine has an additive effect. 
By contrast, paclitaxel administered prior to gemcitabine 
signiﬁ  cantly increases intracellular levels of 2’,2’-diﬂ  uoro-
deoxycytidine-5’-triphosphate, the active component of 
gemcitabine (Theodossiou et al 1998).
Phase II studies
Several phase II studies have been performed with 
gemcitabine/paclitaxel with reported ORR of 40% to 69%, 
TTP of 8 to 9 months, and OS of approximately 12 months 
(Colomer et al 2004; Delﬁ  no et al 2004). Side effects were 
as expected and included neuropathy, myelosuppression 
and nausea, and vomiting (Colomer et al 2004; Delﬁ  no 
et al 2004). In the second-line setting, gemcitabine/
paclitaxel had a response rate of 45% to 55% (Murad et al 
2001). A phase II study by Sánchez-Rovira used biweekly Therapeutics and Clinical Risk Management 2008:4(6) 1159
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combination of doxorubicin at 30 mg/m2 (day 1), paclitaxel 
at 135 mg/m2 (day 2), and gemcitabine at 2500 mg/m2 
(day 2 after paclitaxel) administered biweekly in a 28-day 
cycle for 6 cycles has been shown to have ORR of 83% with 
median TTP of 13.9 months as ﬁ  rst-line therapy.
Phase III registration trial
Based on the response rates and safety data, a phase III 
study was conducted by Albain et al (2008) comparing 
gemcitabine/paclitaxel with paclitaxel alone. Ninety-eight 
centers in 19 countries participated in this trial and enrolled 
529 patients with unresectable, locally recurrent, or measur-
able MBC. Patients were randomized to receive paclitaxel 
(175 mg/m2) on day 1 or paclitaxel (175 mg/m2) on day 1 
with gemcitabine (1250 mg/m2) on days 1 and 8 every 
21 days until disease progression. The primary endpoint 
was OS; secondary endpoints included TTP, ORR, and 
safety. The vast majority of enrolled patients had received 
prior adjuvant anthracyclines (96% in each arm). All those 
who had received prior adjuvant taxanes or prior therapy 
for MBC were ineligible. Patients had a median age of 
53 years (range 23–83), and most patients had metastatic 
(97% per arm) and visceral disease (73% per arm). Based on 
the interim results in May 2004, the US FDA approved the 
combination of gemcitabine/paclitaxel for ﬁ  rst-line therapy 
in MBC in patients who had received prior anthracycline-
based adjuvant chemotherapy. The final results of this 
study were recently published. Demographic data in each 
were similar with a median age of 53 years. Gemcitabine 
was associated with signiﬁ  cantly improved median OS 
(18.6 months vs 15.8 months; p = 0.048), median TTP 
(6.1 months vs 4.0 months; p = 0.00002), and ORR (41.4% vs 
11.5% p = 0.00002), compared with paclitaxel. Toxicity 
data shows that hematologic toxicities, especially grade 
3–4 neutropenia was worse in the combination (47.9% vs 
11.5%) and thrombocytopenia. However, febrile neutropenia 
rates were low in both arms (5%). The combination had 
manageable non-hematological toxicities that were higher 
in the gemcitabine arm (fatigue, motor neuropathy, and 
elevation of transaminases). Dose reductions were 8% for 
gemcitabine and 8% for paclitaxel in the combination arm 
and 2% in the paclitaxel arm. Gemcitabine was omitted in 
7% in the gemcitabine arm compared with less than 1% in 
paclitaxel arm. Fourteen percent in the paclitaxel arm went 
on to receive gemcitabine as part of subsequent therapy 
(Albain et al 2008). Another very important aspect was that 
quality of life (QoL) as measured by Rotterdam Symptom 
checklist Score was signiﬁ  cantly improved with combination 
chemotherapy than with single agent paclitaxel (Moinpour 
et al 2004).
Gemcitabine and docetaxel
Phase II studies
Published phase II data with gemcitabine and docetaxel 
report objective response rates of 59% to 79%, and median 
TTP between 8.5 and 11 months in the ﬁ  rst-line setting. In 
second- and third-line settings published objective response 
rates were as expected lower (36%–54%) with median TTP 
of 7 to 8 months (Kornek et al 2002; Mavroudis et al 2004; 
Pelegri et al 2005).
Phase III study
The combination of gemcitabine and docetaxel was tested 
in a phase III trial by Chan et al (2005). Patients with MBC 
who had received prior anthracyclines either in the adjuvant 
or metastatic setting were randomized to receive either gem-
citabine 1000 mg/m2 (days 1 and 8) plus docetaxel 75 mg/m2 
(day 1) [GD] or capecitabine 1250 mg/m2 twice daily (days 
1–14) plus docetaxel 75 mg/m2 (day 1) every 3 weeks [XD]. 
The primary endpoint of this randomized trial was PFS. 
Secondary endpoints included: safety, QoL, OS, and ORR. 
Patients were stratiﬁ  ed based on: ﬁ  rst- or second-line therapy 
for metastatic disease, presence or absence of visceral metas-
tasis, and prior taxane therapy. Arms were well balanced; 
median age was 55 years; 86% had visceral involvement; 81% 
had 2 metastatic sites; 67% were ER/PR+; 17% were HER2 
over-expressed; 17% received prior taxane; 34% received 
prior chemotherapy for metastatic disease. There was no 
statistically signiﬁ  cant difference in both the arms for efﬁ  cacy 
or adverse effects. PFS was 8.2 months in both arms and ORR 
was 32%. There was also no difference whether the drugs were 
used in ﬁ  rst- or second-line settings. Hematological toxici-
ties were similar including febrile neutropenia (8% vs 13%), 
grade 3–4 neutropenia (85% vs 82%). Grade 3–4 thrombocy-
topenia was more common with GD (11% vs 3%). Overall, 
there were signiﬁ  cantly greater grade 3–4 non-hematologic 
toxicities with XD than GD including: diarrhea (17% vs 7%), 
hand-foot syndrome (26% vs 0%), and mucositis (17% vs 
4%), respectively. It is likely that the dose of capecitabine 
explains the excess of non-hematologic toxicities with XD 
in this trial. Although the approved dose of capecitabine 
is 1250 mg/m2, it is quite rarely used in clinical practice at 
these doses, particularly in the US (Chan et al 2005). Rossi 
et al (2007) showed that lower and better-tolerated doses of 
capecitabine show similar activity to the FDA-approved dose 
of 2500 mg/m2 given daily for 2 of 3 weeks.Therapeutics and Clinical Risk Management 2008:4(6) 1160
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A QoL analysis of the study by Chan et al (2005) was 
conducted by Fumoleau et al (2006) using the Rotterdam 
Symptom Checklist (RSCL). No statistical differences 
between arms were seen for any of the RSCL dimensions 
(p  0.05 at all cycles). By cycle 3, more GD patients reported 
tiredness (58% vs 47%), lack of energy (45% vs 38%), back 
pain (19% vs 9%), and by cycle 2, alopecia (76% vs 66%). 
By cycle 1, more XD patients reported tingling hands/feet 
(15% vs 7%) and burning/sore eyes (14% vs 3%) (Fumoleau 
et al 2006). In a phase III study by O’Shaughnessy et al (2002), 
XD was found to be superior to single-agent docetaxel in ﬁ  rst-
line MBC. Based on the study by Chan et al (2005), GD was 
found to have similar efﬁ  cacy compared with capecitabine/
docetaxel, with fewer non-hematologic toxicities.
Gemcitabine/paclitaxel (GT) 
vs gemcitabine/docetaxel (GD)
A randomized phase II trial was conducted to assess the efﬁ  -
cacy and safety of GT vs GD combination regimens in patients 
previously treated for MBC. GT (G 1250 mg/m2 iv on days 1 
and 8 plus P 175 mg/m2 iv on day 1) or GD (G 1000 mg/m2 iv 
on days 1 and 8 plus D 75 mg/m2 iv on day 1) every 21 days. 
Only 25 patients were randomized due to slow accrual and 
23 were analyzed for response. Overall response rate was 
39% (95% CI 20%–61%) for the GT group and 40% (95% CI 
21%–61%) for the GD group. The median number of cycles 
administered was 6.5 in the GT group and 6.0 in the GD group. 
More febrile neutropenia was seen in 4 patients (16%) in GD 
arm and more neuropathy was seen GT arm 2 patients (8%). 
The authors concluded that GT and GD combination regimens 
are both efﬁ  cacious in the treatment of MBC, with similar 
response rates and manageable toxicity proﬁ  les.
Gemcitabine and nab-paclitaxel
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel, 
ABI-007, Abraxane®) is a solvent-free formulation. Nab-
paclitaxel has several practical advantages over standard 
formulation paclitaxel including a lack of hypersensitivity 
reactions, no need for special tubing for infusion, and shorter 
infusion time. Phase I trials demonstrated that the maximum 
tolerated dose of nab-paclitaxel was 300 mg/m2 on day 1 in 
combination with gemcitabine 1000 mg/m2 on days 1, 8 on 
an every 21-day schedule (Stinchcombe et al 2008). Based 
on these data, phase II studies have been conducted in many 
tumor types including MBC.
Table 1 Phase III randomized trials with gemcitabine/taxane combinations in metastatic breast cancer (MBC)
Treatment Patient characteristics # Patients Overall 
response rate
Median overall 
survival (months)
Progression 
(months)
Reference
Gemcitabine 
1250 mg/m2
(d 1,8) plus paclitaxel 
175 mg/m2 (d 1) 
vs
Paclitaxel 175 mg/m2 
(d 1)every 21 days
No prior chemotherapy 
for MBC; no prior 
taxanes; prior adjuvant 
anthracyclines (95%); 
pisceral disease (73%); 3 
sites of metastases (43%); 
HER-2 status of patients 
not reported
266
263
41.4%a
26.2%
18.6b
15.8
TTP
6.1c
4.0
Albain et al 
2008
Gemcitabine 
1000 mg/m2 (d 1,8) 
plus docetaxel 
75 mg/m2 (d 1) 
vs
Capecitabine 
1250 mg/m2 bid 
(d 1–14) plus docetaxel 
75 mg/m2 (d 1) 
every 21 days
Prior adjuvant/neoad-
juvant and/or ﬁ  rst-line 
chemotherapy for MBC 
allowed: Adj/neoadj (64%); 
MBC (22%); Both (13%); 
prior anthracyclines (70%); 
prior adj/neoadj taxane 
allowed if 6 months 
since completion (10%); 
3 sites of metastases 
(48%); visceral disease 
(84%); HER-2+ (17%); 
HER-2 unknown (35%)
153
152
32%
32%
19.3
21.4
months
Median PFS 8 months 
12-month PFS 24%
Median PFS 8 months 
12-month PFS 30%
Chan et al 
2005
ap = 0.0002; bp = 0.0489; cp  0.0002.
Abbreviations: MBC, metastatic breast cancer; PFS, progression-free survival.Therapeutics and Clinical Risk Management 2008:4(6) 1161
Gemcitabine for metastatic breast cancer
Phase II data
A phase II study of nab-paclitaxel in combination 
with gemcitabine in MBC was conducted by the North 
Central Cancer Treatment Group. Patients were treated 
with nab-paclitaxel 125 mg/m2 followed by gemcitabine 
1000 mg/m2 days 1 and 8 of a 21-day cycle. The primary 
end point of this trial was overall response rate. Preliminary 
results were presented to ASCO 2007 (Roy et al 2007). Fifty 
patients with MBC were enrolled with approximately 80% 
having visceral involvement. Twenty-ﬁ  ve patients (50%) had 
received prior adjuvant chemotherapy, including 15 (30%) 
prior taxanes. Forty-one patients discontinued treatment, due 
to progression (41%), patient refusal (27%), adverse events 
(17%), and alternative treatments (7%). The study reported 
an ORR of 48%: 4 complete response (CR) and 20 partial 
response (PR). The median duration of response and median 
PFS were 6.6 months and 7.9 months, respectively. The most 
common grade 3–4 adverse events included: neutropenia 
(52%), fatigue (26%), anemia (14%), dyspnea (14%), and 
thrombocytopenia (12%). This study therefore demonstrated 
that nab-paclitaxel/gemcitabine is a very active and well 
tolerated regimen in the treatment of MBC (Moreno-Aspitia 
and Perez 2005; Roy et al 2007).
Gemcitabine, nab-paclitaxel, 
and bevacizumab
Lobo et al (2007) reviewed a single-institution experience, 
evaluating safety and preliminary evidence of activity with 
the use of nab-paclitaxel and bevacizumab with and without 
gemcitabine in heavily pretreated HER-2/neu-negative in 
6 women with MBC. The investigators assessed response 
independently of treating physician. RECIST criteria were 
used. Three patients received nab-paclitaxel and bevaci-
zumab at the following doses: nab-P 100 mg/m2, B 10 mg/kg 
every 2 weeks, and 3 patients also received gemcitabine at 
1000 mg/m2; all 3 drugs were given every 2 weeks. Median 
age was 51 (range, 34–69). Two patients had hormone-
receptor positive disease and 3 had triple negative breast 
cancer (ER/PR/Her-2-negative). The median prior number 
of regimens was 3 (range, 2–7). Five patients had been previ-
ously treated with a taxane – 1 received both paclitaxel and 
docetaxel, and 4 docetaxel only. A median of 16 weeks of 
treatment was administered (range 8+ to 32+). First-cycle 
grade 3–4 toxicity was seen in only 1 patient who had a 
baseline grade 2 thrombocytopenia which progressed to 
grade 3. The thrombocytopenia resolved without transfusion 
or hemorrhagic complication. Other treatment-related toxici-
ties were as follows: grade 2 peripheral neuropathy (n = 1); 
grade 2 nausea (n = 1). One patient had a blood pressure of 
210/140 mmHg while non-compliant with her prior anti-
hypertensive therapy. Two patients had conﬁ  rmed PR and 
4 patients had stable disease (Lobo et al 2007).
Gluck et al (2008) reported preliminary data of the ﬁ  rst 
study to examine the efﬁ  cacy of combination therapy with 
nab-paclitaxel, bevacizumab, and gemcitabine as ﬁ  rst-line 
treatment for patients with MBC. Patients (18 years 
with untreated HER2-negative MBC or metastases diag-
nosed 6 months after primary systemic treatment) received 
gemcitabine 1500 mg/m2, nab-paclitaxel 150 mg/m2, and 
bevacizumab 10 mg/kg (each administered intravenously 
over 30 minutes) on days 1 and 15 of 28-day cycles. Cycles 
were repeated for the duration of therapy. PFS is the primary 
endpoint; secondary endpoints include rates of CR or PR, 
OS, safety, and toxicity. So far, 22 of 30 patients (21 female; 
mean age, 54 years) have been enrolled, of whom 17 were 
evaluated for efﬁ  cacy (received 2 cycles), 22 for safety. 
All patients were HER2-negative; 80% were ER+, and 58% 
were PR+. Fourteen (76%) patients achieved PR, and 1 (6%) 
patient had stable disease. All adverse events were grade 1 or 
2, and the most commonly reported side effects were alope-
cia (62%) and fatigue (38%) and rash (23%). Three patients 
were hospitalized because of port site infection (n = 2) and 
hematologic toxicity with neutropenic fever (n = 1). This 
interim analysis demonstrates a very high ORR to ﬁ  rst-line 
combination therapy with nab-paclitaxel, bevacizumab, and 
gemcitabine in patients with MBC. Despite the small sample 
size, these data suggest that this regimen may represent an 
important new option for the ﬁ  rst-line treatment of patients 
with MBC (Gluck et al 2008).
Gemcitabine/paclitaxel/
trastuzumab
Trastuzumab in combination with chemotherapy in HER-2/
neu over-expressing breast cancers improves OS (Slamon et al 
2001). A clinical trial investigated the combinationof paclitaxel 
80 mg/m2/week, gemcitabine 1000 mg/m2 every 2 weeks, and 
trastuzumab 4 mg/kg loading dose and then 2 mg/kg/week 
for a total of 12 weeks in MBC. This study reported an ORR 
of 52.5%; 25% had stable disease and 20% had progressive 
disease. Median duration of response was 14 months. Median 
time to progression is 13.7 months, whereas median survival 
was not reached (Fountzilas et al 2004).
Scheduling of gemcitabine/taxanes
The optimal biologic dosing schedule for taxanes and 
nucleoside analogues is still unclear. Results from several Therapeutics and Clinical Risk Management 2008:4(6) 1162
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preclinical studies have suggested that the administration 
of paclitaxel prior to gemcitabine results in an increase in 
the 2’,2’-diﬂ  uoro-deoxycytidine-5’triphosphate, the active 
metabolite of gemcitabine (Kroep et al 2000). In another 
preclinical study performed in breast cancer cell lines it was 
shown that when gemcitabine was administered 48 hours 
after doxorubicin/paclitaxel combination, there was syn-
ergism. The explanation was that doxorubicin/paclitaxel 
causes G2-M phase block and that the cells re-enter the 
cell-cycle 8 hours after paclitaxel administration, and as they 
enter G-S phase, gemcitabine exerts its cytotoxic activity. 
Based on these preclinical observations, paclitaxel followed 
by gemcitabine is the most commonly used sequence (Zoli 
et al 1999).
The majority of gemcitabine/taxane regimens in MBC 
use every-3-week cycles. However, it had been shown 
that if chemotherapy could be given more frequently at 
the same or lower dose, it would lead to higher responses 
and greater cell death (Fornier and Norton 2005). In the 
adjuvant setting, it is widely accepted that every-2-week 
dose dense chemotherapy with ﬁ  lgrastim support improves 
disease-free survival and improved tolerability, with less 
neutropenia (Citron et al 2003). A phase II study was con-
ducted to evaluate gemcitabine (2500 mg/m2 day 1) and 
paclitaxel (150 mg/m2 on day 1) with or without prophylactic 
ﬁ  lgrastim (G-CSF). Forty-three patients were enrolled. An 
ORR of 78% was observed and 11 patients had CR (26%) 
and, most interestingly, G-CSF was not required for this 
combination (Colomer et al 2004). A lower response rate 
(59%) was obtained when the dose of gemcitabine was 
reduced to 1500 mg/m2 in combination with docetaxel in a 
phase II study, suggesting that a lower dose of gemcitabine 
every 2 weeks may be too low for an effective anti-tumor 
effect (Pelegri et al 2002).
Alternative dosing of gemcitabine/
taxanes
A phase II randomized trial comparing three regimens 
was conducted by Khoo et al (2004). The study compared 
paclitaxel given on days 1 and 8 with the standard regimen 
of every 3 weeks and with docetaxel given on days 1 and 
8 every 3 weeks. A total of 8 cycles were administered and 
prophylactic G-CSF was not routinely allowed. Efﬁ  cacy 
was similar between each gemcitabine/taxane combination 
and toxicity was similar for paclitaxel given weekly or once 
every 3 weeks. Anemia, neutropenia, febrile neutropenia, 
infectious episodes, and diarrhea were more pronounced in 
the gemcitabine/docetaxel combination and were associated 
with higher use of blood transfusions, G-CSF, and antibiotics 
(Khoo et al 2004).
Single-agent sequential therapy 
vs combination therapy: when is one 
drug enough in MBC?
Despite emerging evidence that combination chemotherapy, 
including here a combination of cytotoxic chemotherapy 
with monoclonal antibodies, eg, bevacizumab and trastu-
zumab, there are situations when single-agent sequential 
therapy would be more appropriate in MBC and clearly 
2 or 3 drugs are “too much”: (i) poor performance status 
patients and/or elderly or non-elderly patients with multiple 
co-morbidities that would increase the likelihood of adverse 
toxicities with combination chemotherapy; (ii) patients 
with rather minimal signs or symptoms and/or with few 
metastasitc sites, who are thus asymptomatic from their 
disease. Consequently, in these situations single sequential 
drug use would have less propensity for adverse toxicities 
and consequently would help to maintain improved QoL in 
patients as long as possible.
Moving speciﬁ  cally to combinations of biologic and 
targeted agents to gemcitabine-taxane doublets in the treat-
ment of HER-2 unampliﬁ  ed MBC, although many studies 
are underway only the addition of bevacizumab to weekly 
paclitaxel has been shown to signiﬁ  cantly improve PFS. 
In the ECOG 2100 randomized phase III trial the addition 
of bevacizumab to weekly paclitaxel (3 out of 4 weeks) 
improved PFS by almost 6 months (11.8 vs 5.9 months; 
p  0.001) with no difference in OS (Miller et al 2007). 
Many other studies are ongoing, such as the combination of 
bevacizumab and docetaxel, the combination of paclitaxel, 
gemcitabine, and bevacizumab, and many others. At this 
point no phase III data are available to indicate whether the 
addition of gemcitabine to a bevacizumab/taxane doublet 
as ﬁ  rst-line therapy for HER-2 unampliﬁ  ed MBC results in 
superior clinical outcomes. Therefore, the treating medical 
oncologist should have an open discussion with the patient 
to determine the goals of therapy and the limitations of the 
current clinical data. Nevertheless, there are certain situa-
tions where it may be reasonable to recommend combination 
bevacizumab/taxane chemotherapy with or without gem-
citabine for ﬁ  rst-line treatment of HER-2 unampliﬁ  ed MBC: 
(i) patients with more metastatic tumor burden; (ii) symptom-
atic patients; (iii) triple negative disease; (iv) younger age; 
(v) other poor prognostic factors, eg, 5 circulating tumor 
cells, short interval between adjuvant therapy, and diagnosis 
of MBC. Subsequent lines of treatment would probably be Therapeutics and Clinical Risk Management 2008:4(6) 1163
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equivalently treated with a single sequential approach as in 
the past unless new data emerge.
Conclusions
Despite recent advances in chemotherapeutic agents for 
MBC, it is still an incurable disease and the purpose of 
chemotherapy remains that of relieving symptoms and 
improving QoL. It is also widely realized that response rates 
do sometimes correlate with survival and hence rational drug 
combinations for effective cytotoxicity with good tolerability 
are essential for the management of MBC. The combination 
of gemcitabine and taxanes is an effective regimen that is 
well tolerated with good response rates, as illustrated in this 
review. This is all the more true in anthracycline-resistant 
or anthracycline-refractory cases. The combination of 
gemcitabine/paclitaxel has been approved by the FDA for 
MBC and the other two combinations (gemcitabine/docetaxel 
and gemcitabine/nab-paclitaxel) are also reasonable alterna-
tives given the phase II data reviewed in this article.
We can conclude that a gemcitabine/taxane combination 
is very promising and in one study has shown an overall 
survival advantage. Other gemcitabine/taxane combinations 
with agents targeting the vascular endothelial growth factor 
receptor need to be further explored in phase III trials. We 
can also conclude that the era of single-agent sequential 
therapy for MBC is over for many patients, based on several 
studies showing superiority. It remains to be seen in what 
sequence these drug combinations used in ﬁ  rst-, second-, 
third-, and fourth-line settings offers the best potential for 
time to progression, response rates, and survival while pre-
serving QoL.
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